Repurposed drugs for COVID-19: threshold and proof requirements for trials

用于治疗新冠肺炎的现有药物:试验的门槛和证明要求

阅读:1

Abstract

Since the coronavirus outbreak, various media outlets across the globe have disseminated and promoted stories of kindness as registers for COVID-19 response. These narratives of kindness appeal to the human capacity to do good, inviting the public to ‘make a difference’ by performing altruistic acts of helping those who are less fortunate or in a time of need. However, there is a dark side to these narratives, one that does not serve those who are precarious, underprivileged or marginalised, by obfuscating and erasing necessary conversations on the transformative policies and infrastructure changes needed to address fundamental structural issues underlying the deep inequalities we inhabit in a COVID world.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。